论文部分内容阅读
目的 :为进一步提高无症状人群普查中大肠癌的检出率 ,降低普查费用。方法 :在既往序贯粪隐血筛检方案 (S方案 )、粪隐血与微量白蛋白互补方案 (SA方案 )的基础上 ,探索了互补序贯筛检方案 ,即粪隐血与微量白蛋白互补→肠道脱落细胞序贯方案 (SAD方案 )。结果 :经 392例已知患者验证 ,SAD方案大肠癌检出敏感性显著高于S方案 (P<0 .0 1) ,与SA方案无显著差异 (P >0 .0 1) ,特异性显著高于SA方案 (P <0 .0 1) ,在各方案中每检出 1例大肠癌患者所用经费最低 ( 32 3.7元 /例 )。结论 :SAD方案筛检大肠肿瘤敏感性高 ,特异性强 ,效 /价比最优。
Objective: To further improve the detection rate of colorectal cancer in census of asymptomatic population and reduce the cost of census. Methods: On the basis of previous sequential fecal occult blood screening protocol (S protocol), fecal occult blood and microalbumin complementary protocol (SA protocol), a complementary sequential screening protocol was explored, namely fecal occult blood and microalbumin complementarity → Gut exfoliative cell sequential protocol (SAD protocol). Results: The sensitivity of SAD was significantly higher than that of S (P <0. 01) in 392 known patients. There was no significant difference (P> 0. Higher than the SA program (P <0. 01), the lowest cost per eligible colorectal cancer detected in each of the programs (32.3 yuan / case). Conclusion: SAD screening of large intestinal tumors with high sensitivity, specificity, efficiency / price ratio of the best.